A5040637578- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- RNA modifications and cancer
- Chromatin Remodeling and Cancer
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
Tufts Medical Center
2022-2024
Guidelines recommend somatic and germline testing for men with advanced prostate cancer (PCa). Barriers to widespread implementation result in underutilization of testing. Somatic alone risks missing pathogenic variants (PGVs). We sought determine whether the addition tumor-only sequencing improves detection PGVs PCa. Secondarily, we define added value combining optimize clinically actionable alterations.We analyzed results independent from 100 PCa a prospective clinical trial...
Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer (PCa). Better biomarkers are needed to predict responses ICIs. We sought demonstrate that a panel-based mutational signature identifies mismatch repair (MMR) deficient (MMRd) PCa and is biomarker of response pembrolizumab. Clinico-genomic data was obtained for 2664 patients with sequenced at Dana-Farber Cancer Institute (DFCI) Memorial Sloan Kettering (MSK). Clinical outcomes were collected metastatic...
Prior studies characterized the association of molecular alterations with treatment-specific outcomes in KRAS-mutant (KRAS
8549 Background: Biomarkers to guide the application of CTLA-4 inhibitors with anti-PD-(L)1 in untreated EGFR/ALK-negative metastatic non-small cell lung cancer (mNSCLC) are underexplored. Methods: Patients ECOG performance status 0-1 and mNSCLC who received dual immune checkpoint inhibitor (ICI) therapy, or single agent PD-(L)1 alone (ICI-mono) chemotherapy (ICI-chemo) at three institutions were analyzed. Clinical progression-free survival (PFS), overall (OS) primary outcomes. progressive...
Abstract Background The PARP inhibitor (PARPi) olaparib is approved for homologous recombination repair (HRR) gene‐altered metastatic castration‐resistant prostate cancer (mCRPC). However, there significant heterogeneity in response to PARPi patients with mCRPC. Better clinical biomarkers are needed identify likely benefit from PARPi. Methods Patients adenocarcinoma and panel sequencing at Dana‐Farber Cancer Institute were identified. Mutational signature analysis was performed using SigMA...
<h3>Background</h3> Immunotherapy (IO) has continued to revolutionize cancer therapy particularly in difficult-to-treat cancers such as non-small cell lung (NSCLC). However, durable responses among patients treated with IO monotherapy (IO-mono) are observed less than half of patients.<sup>1</sup> Combining chemotherapy (IO-chemo) increases response rates but also raises financial burden and toxicity.<sup>2</sup> It is thus paramount importance optimize treatment selection avoid unnecessary...
Abstract Background. The PARP inhibitor (PARPi) Olaparib is FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring a deleterious alteration in specific homologous recombination (HR) genes based on results the PROfound trial. Qualifying HR gene alterations include BRCA1, BRCA2, ATM (Cohort A), and BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51C, RAD51D B). However, there heterogeneity degree to which different associate with response PARPi....
Abstract Background: Lung adenocarcinoma (LUAD) is a disease classified by molecular markers. In KRAS-mutant LUAD, STK11 and KEAP1 mutations are associated with decreased overall survival (OS), but predictors of metastasis have been poorly defined. this study, we identify clinical genomic metastatic LUAD. Methods: Patients LUAD profiled targeted next generation sequencing (OncoPanel) were included. Stage, histology, recurrence-free assessed. Clinical features between vs non-metastatic...